Search

Displaying results 2531 - 2540 of 7540 in total
  1. Drug

    Nialamide

    go.drugbank.com/drugs/DB04820
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.

    Categories: Monoamine Oxidase Inhibitors, Non-Selective, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: N-Isonicotinoyl-N'(beta-N-benzylcarboxamidoethyl)hydrazine, N-(2-(Benzylcarbamyl)ethylamino)isonicotinamide
  2. Drug

    Chlorambucil

    go.drugbank.com/drugs/DB00291
    ApprovedInvestigational

    Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)

    Synonyms: N,N-di-2-chloroethyl-γ-p-aminophenylbutyric acid, N,N-di-2-chloroethyl-gamma-p-aminophenylbutyric acid
  3. Drug

    Magnesium silicate

    go.drugbank.com/drugs/DB13249
    ApprovedWithdrawn

    [L2603] Under the FDA, magnesium silicate is determined as a member of the substances generally recognized as safe (GRAS) to be used as an anticaking agent.[L2605]

  4. Drug

    Lyme disease vaccine (recombinant OspA)

    go.drugbank.com/drugs/DB00045
    ApprovedWithdrawn

    Lipoprotein OspA is a single polypeptide chain of 257 amino acids with lipids covalently bonded to the N terminus. It is conjugated with alum (aluminum hydroxide) as an adjuvant. … Vaccine against Lyme disease that contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli.

  5. Drug

    Demecarium

    go.drugbank.com/drugs/DB00944
    Approved

    Cholinesterase inhibitors prolong the effect of acetylcholine, which is released at the neuroeffector junction of parasympathetic postganglion nerves, by inactivating the cholinesterases that break it … The outflow of the aqueous humor is facilitated, which leads to a reduction in intraocular pressure.

  6. Drug

    Acalabrutinib

    go.drugbank.com/drugs/DB11703
    ApprovedInvestigational

    [L42795,L42800] Unlike Calquence capsules, the co-administration of Calquence tablets and PPIs does not have an effect in the pharmacokinetics of acalabrutinib. … expected to demonstrate fewer adverse effects owing to minimized bystander effects on targets other than BTK.

  7. Drug

    Clioquinol

    go.drugbank.com/drugs/DB04815
    ApprovedVet approvedWithdrawn

    Clioquinol was withdrawn in 1983 due to neurotoxicity.

    Mixtures: Neo Vagex
  8. Drug

    Vanzacaftor

    go.drugbank.com/drugs/DB18373
    ApprovedInvestigational

    [L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor … It is used alongside other CFTR correctors and CFTR potentiators to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis.

  9. Drug

    Tenapanor

    go.drugbank.com/drugs/DB11761
    ApprovedInvestigational

    Tenapanor is a novel, small molecule medication approved in September 2019 for the treatment of constipation-predominant irritable bowel-syndrome (IBS-C). It was first designed and synthesized in 2012. As an inhibitor of the sodium/hydro...

  10. Drug

    Cat dander extract

    go.drugbank.com/drugs/DB13904
    Approved

    An allergic reaction to cats is induced by the presence of antigen-specific IgE antibodies that are bound to specific receptors on mast cells and basophils. … Cat dander extract can be used in immunotherapy in individuals who cannot avoid exposure to cat allergens to initiate hyposensitization.